louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04058912: PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas
Official title: RELATIONSHIP OF LOW-OVER RESERVE WITH PTEN-AKT-FOXO3 GENE EXPRESSION IN THE PRESENCE OF ENDOMETRIOMAS
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression
Lead sponsor: Uludag University
Sponsor class: OTHER
First posted: 2019-08-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is the patients examined for ovarian endometriomas and other benign ovarian pathologies

Brief summary: In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene expression and decrease in ovarian reserve in the presence of endometrioma and other benign ovarian pathologies.

Detailed description: It is known that the presence of endometrioma negatively affects ovarian reserve. The development of endometriosis and the effect of the presence of endometrioma on ovarian reserve due to decreased PTEN expression are considered. This study was designed to compare ovarian PTEN-AKT-FOXO3 gene expression and ovarian reserve in patients with underwent surgery caused by endometrioma and those who had ovarian pathology due to other benign causes and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.

Eligibility criteria: Inclusion Criteria:

* 1) To be in the range of 18-40 years 2) Patients with an operation indication with \>=5 cm endometrioma 3) Patients with operation plan due to non-endometrioma ovarian pathologies

Exclusion Criteria:

* 1)Patients over the age of 40 2)Patients with suspected malignancy 3)Follow-up patients without indications for operation

Primary outcomes:
measure: PTEN AKT FOXO3 gene expression
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Uludag University Hospital, Department of Obstetrics and Gynecology
state: Nilufer
city: Bursa
country: Turkey
facility: Uludag University Hospital, Department of Obstetrics and Gynecology
state: Nilufer
Study officials:
affiliation: ULUDAG UNIVERSITY HOSPITAL BURSA TURKEY
name: GURKAN UNCU, Prof
role: STUDY_DIRECTOR
References:
citation: Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014 Feb;29(2):324-36. doi: 10.1093/humrep/det387. Epub 2013 Oct 23.
citation: Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20.
Clinical trial NCT00125112: Internet Weight Control for Bingeing Adolescents
Official title: Internet Weight Control for Bingeing Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Eating Disorders
Keywords: binge eating
weight loss
obesity
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2005-07-29
Enrollment: 120
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if an internet-based intervention designed to reduce binge eating and improve healthy weight regulation skills will result in reductions in binge eating and weight loss, or weight maintenance, in overweight adolescents who binge eat.

Detailed description: The purpose of this study is to determine if an internet-based intervention designed to reduce binge eating and improve healthy weight regulation skills will result in reductions in binge eating and weight loss, or weight maintenance, in overweight adolescents who binge eat.

Eligibility criteria: Inclusion Criteria:

* Female and male high school students in Hayward Unified School District or Meridian School District
* 85th or greater percentile for age-adjusted weight
* Objective binge eating one or more times weekly for a duration of ≥ 3 months
* Access to a computer with internet access
* English literacy at a sixth grade reading level

Exclusion Criteria:

* Current (or history of) diagnosis of anorexia or bulimia nervosa
* Active suicidal ideation
* Current enrollment in a formal weight loss or binge eating program (e.g., Weight Watchers)
* Any medical condition in which the actual condition or treatment affects weight and/or appetite (i.e., cancer, diabetes)

Primary outcomes:
measure: Frequency of binge eating; weight
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University Department of Psychiatry and Behavioral Sciences
state: California
Study officials:
affiliation: Stanford University Department of Psychiatry and Behavioral Sciences
name: C. Barr Taylor, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jones M, Luce KH, Osborne MI, Taylor K, Cunning D, Doyle AC, Wilfley DE, Taylor CB. Randomized, controlled trial of an internet-facilitated intervention for reducing binge eating and overweight in adolescents. Pediatrics. 2008 Mar;121(3):453-62. doi: 10.1542/peds.2007-1173.
Clinical trial NCT00351312: Creation of a Pressure Reducing Areas in Socks
Official title: Evaluation of Foot Pressure in Volunteers Wearing Socks Weaved With Pressure Reducing Soles
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pressure Ulcers
Keywords: Pressure ulcers
socks
foot pressure
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2006-07-12
Enrollment: 4
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Evaluation of the ability of socks weaved with pressure relieving areas to reduce the pressure on the foot when weight bearing.

Detailed description: Increased pressure in weight bearing areas of the foot, especially in insensate feet may lead to the development of pressure sore. The creation of socks with pressure relieving areas by special weaving technique may prevent the development of these complications.

Three (3) volunteers will be examined walking on a Tekscan pressure mat, barefoot and then wearing socks weaved in a new technique, from cotton, nylon and acrilan.

Eligibility criteria: Inclusion Criteria:

* healthy volunteers

Exclusion Criteria:

* foot deformity

Primary outcomes:
measure: Pressure measurement
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Hashomer
country: Israel
facility: Motion Analysis Laboratory, Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Uri Givon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00502112: A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Official title: A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid®) in Patients With Myelodysplastic Syndromes (MDS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Myelodysplastic Syndrome (MDS)
Keywords: Lintuzumab
Antigens, CD33
Antibodies, Monoclonal
Combined Modality Therapy
Myelodysplastic Syndromes
Hematologic Diseases
Preleukemia
Lead sponsor: Seagen Inc.
Sponsor class: INDUSTRY
First posted: 2007-07-17
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycles of combination therapy.


Eligibility criteria: Inclusion Criteria:

1. Disease confirmation of MDS.
2. Between 5% and 30% blasts in the bone marrow.
3. Received treatment for cytopenias within 2-months
4. ECOG ≤ 2.

Exclusion Criteria:

1. Received prior therapy with lenalidomide, gemtuzumab ozogamicin (Mylotarg®).
2. Received chemotherapy/radiotherapy within 4 weeks of study registration.
3. Received prior bone marrow transplant.
4. 5q- chromosomal deletion in malignant cells.

Primary outcomes:
measure: The incidence of adverse events and lab abnormalities
timeFrame: 1 month after last dose
Secondary outcomes:
measure: Antitumor activity
timeFrame: Every other 21-day cycle
measure: Pharmacokinetic (PK) profile and immunogenicity (Human Anti-Human Antibody; HAHA)
timeFrame: 1 month after last dose
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Denver
country: United States
facility: Rocky Mountain Cancer Center
state: Colorado
city: Washington
country: United States
facility: Georgetown University
state: District of Columbia
city: Atlanta
country: United States
facility: Georgia Cancer Specialists
state: Georgia
city: New York
country: United States
facility: St.Vincent's Comprehensive Cancer Center
state: New York
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Sioux Falls
country: United States
facility: Avera Cancer Institute
state: South Dakota
Study officials:
affiliation: Seagen Inc.
name: Eric Sievers, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05803512: Predicting Female Pelvic Tilt and Lumbar Angle Using Machine Learning in Case of Urinary Incontinence and Sexual Dysfunction
Official title: Predicting Female Pelvic Tilt and Lumbar Angle Using Machine Learning in Case of Urinary Incontinence and Sexual Dysfunction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: The Purpose of This Study is to Predicting Female Pelvic Tilt and Lumbar Angle Using Machine Learning in Case of Urinary Incontinence and Sexual Dysfunction
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2023-04-07
Enrollment: 92
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 40
Standard ages: ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Their ages varied from 30to 40years, their body mass index (BMI) was 25-30 kg/m2 and a number of parities ≤ three normal vaginal deliveries

Brief summary: The purpose of this study is to Predicting female pelvic tilt and lumbar angle using machine learning in case of urinary incontinence and sexual dysfunction

Detailed description: 92 patients were distributed randomly into two groups. The first group will be measured pelvic tilt, lumbar angle by spinal mouse and force of contraction of pelvic floor muscles by ultrasound imaging, UDI-6 and FSFI questionnaires for urinary incontinence female The second group will be measured pelvic tilt, lumbar angle by spinal mouse device and force of contraction of pelvic floor muscles by ultrasound imaging, UDI-6 and FSFI questionnaires for normal females.

Patients will be examined by radiologist with medical ultrasound imaging and by me with spinal mouse device.

Eligibility criteria: Inclusion Criteria:

* - Their ages varied from 30to 40years, their body mass index (BMI) was 25-30 kg/m2 and a number of parities ≤ three normal vaginal deliveries, at least two years and Subjects hadn't received drugs, patients with mild and moderate urinary incontinence with sexual dysfunction

Exclusion Criteria:

- 1. History of spinal surgery or spinal fracture. 2. Volunteers with a history of a recto-vaginal or vesico-vaginal fistula, undiagnosed uterine bleeding urinary tract infection, diabetes, intrauterine device, chest and/or cardiac disease and using any drugs for urinary incontinence 3. Serious diseases, such as heart disease, kidney, liver diseases, gastric ulcer or duodenal ulcer.

4. A history of bronchial asthma or any chest disease. 5. Uncontrolled diabetes or hypertension. 6. Patients with peacemaker or any metal implant on the treated area. 7. Cancer or patient with past history of tumor excision.

Primary outcomes:
measure: Pelvic tilt, lumbar angle
timeFrame: 2 months
Secondary outcomes:
measure: Force of contraction of pelvic floor muscles
timeFrame: 2 months
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Deraya university
Study officials:
affiliation: Deraya University
name: tarek Abd Elhafez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06886412: Non-Pharmacological Methods for Reducing Pain During Vaccination in Infants
Official title: The Effect of Breastfeeding and Maternal Holding on Reducing Pain During Vaccination in Infants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pain
Breast Feeding
Maternal Behavior
Keywords: Pain
Vaccines
Nursing
Breastfeeding
Maternal holding
Infants
Lead sponsor: University of Yalova
Sponsor class: OTHER
First posted: 2025-03-20
Enrollment: 84
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled and quasi-experimental research
Primary purpose: SUPPORTIVE_CARE

Brief summary: Pain management in infants is a medical responsibility of all members of the healthcare team, and nurses hold a privileged role in this regard. The primary goal of pain management is to accurately assess and identify the infant's pain at an early stage, support the development of coping mechanisms through both pharmacological and non-pharmacological methods, and minimize the pain experience as much as possible. Pain management achieved through non-pharmacological interventions constitutes a safe, non-invasive, cost-effective, and independently performed nursing practice. This randomized controlled study was conducted to determine the effect of non-pharmacological methods, specifically maternal holding and breastfeeding, on reducing pain during vaccination in infants.


Eligibility criteria: Inclusion Criteria:

* Being healthy,
* Aged between 4 weeks and 6 months,
* Parents have given verbal and written consent to participate in the study,
* Born at term (37 weeks of gestation or later),
* Scheduled for vaccination under the Ministry of Health's vaccination program,
* Not having taken analgesics/antipyretics in the last 4 hours before the procedure,
* Having a normal body temperature (between 36.5°C and 37.1°C).

Exclusion Criteria:

* Having a chronic or mental illness, or a congenital anomaly,
* Being older than 6 months,
* Having a body temperature above 37.1°C,
* Receiving analgesics, sedatives, or any other medication.

Primary outcomes:
measure: Evaluation of pain and crying duration in the infant held in the mother's arms during the vaccination procedure
timeFrame: Two minutes before the procedure, during the procedure, and three minutes after the procedure.
measure: Evaluation of pain and crying duration in the infant held in the breast feeding during the vaccination procedure
timeFrame: Two minutes before the procedure, during the procedure, and three minutes after the procedure.
Secondary outcomes:
Other outcomes:
Locations:
city: Yalova
country: Turkey
facility: Yalova University
Study officials:
affiliation: Yalova Unıversıty
name: EMEL AVÇİN, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00438412: Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Obstructive Sleep Apnea
Keywords: Noradrenalin
Endothelin-1
Angiotensin II
Arginine vasopressin
Aldosterone
Renin
Atrial natriuretic peptide
Brain natriuretic peptide
Blood pressure
Apnea
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2007-02-22
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults, males and females,age 30 -65

Brief summary: The mechanisms involved in development and maintenance of hypertension in obstructive sleep apnea are not clarified.

We hypothesize that patients with obstructive sleep apnea have an abnormal level of some vasoactive hormones during apneic events during sleep.


Eligibility criteria: Patients with Obstructive sleep apnea

Inclusion Criteria:

* Severe obstructive sleep apnea (apnea-hypopnea index \> 30)

Exclusion Criteria:

* Drug or alcohol abuse
* Pregnancy
* History or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs
* Diabetes

Healthy Controls

Inclusion Criteria:

* Apnea-hypopnea index \< 10

Exclusion criteria:

* Drug or alcohol abuse
* Pregnancy
* History or clinical signs of disease in the heart, lungs, brain, liver, kidneys or endocrine organs
* Diabetes

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Holstebro
country: Denmark
facility: Department of Medical Research, Holstebro Hospital
Study officials:
affiliation: Regional Hospital Holstebro
name: Erling B Pedersen, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT05321212: Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
Official title: Efficacy (Systemic and Cerebral) and Safety of PEMbrolizumab PD-L1-positive (More Than 50% of Tumor Cells), Advanced Non-small-cell Lung Cancer : A Study of Real Life in Brittany .
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Non-Small-Cell Lung
Immunotherapy
Keywords: pembrolizumab
first line treatment
PDL1 TPS > 50%
brain efficacy
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non-small-cell lung cancer with PDL1 TPS \> 50% treated in first line with pembrolizumab

Brief summary: This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.


Eligibility criteria: Inclusion Criteria:

* histologically or cytologically confirmed NSCLC PD- L1 TPS ≥ 50% stage III and IV WHO performance status of 0, 1 or 2 adequate organ function

Exclusion Criteria:

* previous EGFR or ALK aberrations positive test for hepatitis B or C virus indicating acute or chronic infection known history of testing positive for human immunodeficiency virus (HIV) severe, uncontrolled autoimmune disease.

Primary outcomes:
measure: progression free survival with pembrolizumab
timeFrame: time from initiation of pembrolizumab to the date of disease progression or death ( 20 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
city: Quimper
country: France
facility: CHIC de QUIMPER
Study officials:
References:
Clinical trial NCT00295412: The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
Official title: The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Substance Use Disorders
Lead sponsor: Université de Montréal
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2006-02-23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.


Eligibility criteria: Inclusion Criteria:

* Patients with as schizophrenia spectrum disorder
* Patients with a comorbid substance use disorder

Exclusion Criteria:

* Patients already on quetiapine or clozapine
* Patients hospitalized or acutely ill
* Total score lower than 65 on the PANSS
* Pregnancy
* Female subjects of childbearing potential without adequate contraception
* Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
* Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Centre de recherche Fernand-Seguin
state: Quebec
Study officials:
affiliation: Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Departement of Psychiatry, Faculty of medicine, University of Montreal
name: Emmanuel Stip, Md, MSc, CSPQ
role: PRINCIPAL_INVESTIGATOR
References: